Immunotech Biopharm : CHANGE OF SENIOR MANAGEMENT

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Immunotech Biopharm Ltd

永泰生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6978)

CHANGE OF SENIOR MANAGEMENT

The board of directors (the "Board") of Immunotech Biopharm Ltd (the "Company", together with its subsidiaries, the "Group") hereby announces that on 13 April 2021 (after trading hours), Dr Kim Ho-un ("Dr Kim") has tendered his resignation as the co-chief technology officer ("CTO") of the Group and Dr Lee Hyun-soo ("Dr Lee") has been appointed as the new co-CTO on 13 April 2021.

Dr Lee received a Bachelor of Science and Master of Science in microbiology at Seoul National University in February 1985 and February 1987, respectively. He later received a Ph.D in molecular biotechnology at Korea Advanced Institute of Science and Technology in October 2004.

From January 1987 to April 2005, Dr Lee served as a senior researcher at Research Institute of Pharmaceuticals, CJ Group, a conglomerate in Republic of Korea ("Korea"). From June 2005 to April 2021, he served as the director of research institute in a number of biotechnology companies in Korea. Since March 2016, he has been serving as a non-executive director of Aprogen Inc, a biopharmaceutical company in Korea. Dr Lee has extensive research and development experience in microbiology and biotechnology.

Each of Dr Kim and Dr Lee confirms that he has no disagreement with the Board. The Board would like to express its sincere gratitude to Dr Kim for his contributions to the Company during his tenure of office, and warmly welcomes Dr Lee in joining the senior management team of the Company.

By order of the Board

Immunotech Biopharm Ltd

Tan Zheng

Chairman and executive Director

Hong Kong, 13 April 2021

As at the date of this announcement, the Board of the Company comprises Mr Tan Zheng as Chairman and executive Director, Dr Wang Yu and Mr Jung Hyun Chul as executive Directors, Mr Si Xiaobing, Mr Lu Yuan and Mr Li Yuezhong as non-executive Directors, and Mr Wang Yingdian, Mr Ng Chi Kit and Ms Peng Sujiu as independent non-executive Directors.